Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16675697 | 1.00 | ALDH1A1 (0.37) | ALDH1A1KDM4EKDM2BALOX15TSHR | |
| SCHEMBL27363758 | 0.93 | KDM4E (0.35) | ALDH1A1KDM4EKDM2BALOX15TSHR | |
| SCHEMBL24204537 | 0.91 | ALDH1A1 (0.39) | ALDH1A1KDM4EKDM2BALOX15TSHR | |
| SCHEMBL14355437 | 0.91 | — | — | |
| SCHEMBL15089010 | 0.87 | ALDH1A1 (0.49) | ALDH1A1KDM4ETSHRTDP1USP2 | |
| SCHEMBL15088721 | 0.87 | ALDH1A1 (0.49) | ALDH1A1KDM4ETSHRTDP1USP2 | |
| SCHEMBL736095 | 0.86 | KDM4E (0.47) | ALDH1A1KDM4EKDM2BALOX15KMT2A | |
| SCHEMBL1646548 | 0.86 | KDM4E (0.47) | ALDH1A1KDM4EKDM2BALOX15KMT2A | |
| SCHEMBL736305 | 0.86 | KDM4E (0.47) | ALDH1A1KDM4EKDM2BALOX15KMT2A | |
| SCHEMBL20080900 | 0.85 | ALDH1A1 (0.44) | ALDH1A1KDM4ETSHRTDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| EP-3242875-B1 | 4,5-DIHYDROIMIDAZOLE DERIVATIVES AND THEIR USE AS HISTONE DEMETHYLASE (KDM2B) INHIBITORS | GENENTECH INC (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3660004-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| WO-2018044808-A1 | INHIBITORS OF DUAL LEUCINE ZIPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | ALDH1A1 4351/4885KDM4E 983/4885KDM2B 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.